News Releases

2019

Corporate
2019.04.04
Announcement on Candidates of Members of Board of Directors, Members of Audit & Supervisory Board and Corporate Officers
R&D
Apr.03.2019
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
R&D
Mar.28.2019
ONO Submits Supplemental Application of Opdivo® (Nivolumab) for Indication of MSI-H Unresectable Advanced or Recurrent Colorectal Cancer That Has Progressed Following Chemotherapy, for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan
R&D
Mar.27.2019
A selective sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga receives additional regulatory approval on indication and dosage and administration in type-1 diabetes in Japan
Licensing
Mar.27.2019
ONO Announces a Strategic Drug Discovery Alliance Agreement with Cancer Research UK and LifeArc for Cancer Immunotherapy
R&D
Mar.26.2019
A Short-Acting Selective β1 Blocker, ONOACT® for Intravenous Infusion 50mg/150mg Approved for Additional Indication of Ventricular Arrhythmia in Japan
R&D
Mar.19.2019
ONO Submits Supplemental Application of Kyprolis® for Intravenous Injection, a Proteasome Inhibitor, for Additional Dosage and Administration for the Treatment of Relapsed or Refractory Multiple Myeloma in Japan
Licensing
Mar.18.2019
Ono Enters into Research Collaboration Agreement with twoXAR, Inc.
R&D
Mar.14.2019
ONO and Novartis Pharma Receive a Supplemental Approval for Formulation with New Ingredient of Rivastach® Patch and Exelon® Patch for the Treatment of Alzheimer's Disease Dementia (40.5KB)
R&D
Mar.11.2019
BMSKK and ONO Submit Supplemental Applications of Orencia® for I.V. Infusion, Orencia® Syringe for S.C. Injection and Orencia® Autoinjector for S.C. Injection, a Selective T-cell Co-Stimulation Modulator, for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis (55.7KB)
R&D
Feb.27.2019
ONO Submits an Application for Manufacturing and Marketing Approval of Opicapone (ONO-2370) for the Treatment of Parkinson's Disease Patients with Motor Fluctuations in Japan (43.6KB)
Products
Feb.26.2019
Launch of Demser® Capsule 250 mg, a Tyrosine Hydroxylase Inhibitor in Japan (83.8KB)
Products
Feb.26.2019
Launch of BRAFTOVI® Capsule 50 mg, a BRAF Inhibitor and MEKTOVI® Tablet 15 mg, a MEK Inhibitor in Japan (175KB)
CSR
Feb.25.2019
ONO Certified in 2019 as Outstanding Health and Productivity Management Organization (White 500) (138KB)
R&D
Feb.19.2019
Ono and Seikagaku Announce the Topline Results from a Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan (96.1KB)
R&D
Feb.15.2019
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (51.8KB)
R&D
Feb.15.2019
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer (48.2KB)
Licensing
Jan.31.2019
ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program (108KB)
CSR
Jan.22.2019
ONO Selected by CDP as a Climate Change A List Company in 2018 (76.3KB)
R&D
Jan.18.2019
Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy in Taiwan (71.4KB)
R&D
Jan.15.2019
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma (47.8KB)
R&D
Jan.15.2019
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer (36.2KB)
R&D
Jan.10.2019
Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma (35.3KB)
R&D
Jan.09.2019
Opdivo® (Nivolumab) Demonstrates a Significant Extension in Overall Survival Versus Chemotherapy in Patients with Unresectable Advanced or Recurrent Esophageal Cancer in Phase III Clinical Study (42.4KB)
R&D
Jan.08.2019
ONO Receives Manufacturing and Marketing Approval in Japan for Demser® Capsule, a Tyrosine Hydroxylase Inhibitor, for Improvement of Status of Catecholamine Excess Secretion and its Accompanying Symptoms in Patients with Pheochromocytoma (64.7KB)
R&D
Jan.08.2019
ONO Receives a Manufacturing and Marketing Approval for BRAFTOVI® Capsule, a BRAF Inhibitor and MEKTOVI® Tablet, a MEK Inhibitor for Indication of Unresectable BRAF-Mutant Melanoma in Japan (58.3KB)
CSR
Jan.07.2019
ONO Listed in FTSE4Good Index Series and FTSE Blossom Japan Index for Socially Responsible Investment (121KB)